Onco360 Oncology Pharmacy

Overview

Onco360 Oncology Pharmacy is an oncology-only specialty pharmacy and clinical support company used in cancer-drug launch and limited-distribution networks. The company is headquartered in Louisville, Kentucky, dispenses nationally through accredited oncology pharmacies, and operates as a PharMerica / BrightSpring Health Services specialty-pharmacy brand.

For manufacturers, the core question is whether the product needs a pharmacy partner built specifically around oncology access, not whether Onco360 can dispense specialty medications in general. Onco360 is most relevant when a launch requires coordinated benefit verification, prior authorization, financial assistance, clinical counseling, shipment coordination, and manufacturer reporting around oral, injectable, or infused cancer therapies.

Specialty Pharmacy Capability Model

The framework below standardizes how Rx Almanac evaluates specialty-pharmacies capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Onco360 Oncology Pharmacy is evaluated as oncology-only specialty pharmacy and clinical support company used in cancer-drug launch and limited-distribution networks.

Capability	Buyer should compare	Onco360 Oncology Pharmacy readout
Specialty dispensing and channel access	Licensed dispensing footprint, payer network access, LDD participation, referral capture, and ability to serve the target patient geography.	Major fulfillment handoff. Onco360 is repeatedly named in public launch announcements as a national or specialty pharmacy partner for oncology therapies.
Benefits, PA, and reimbursement support	Benefit investigation, PA support, appeals coordination, copay/PAP routing, and reimbursement troubleshooting at the pharmacy edge.	Major coverage workflow. Best fit is a launch where patient start depends on oncology-specific access navigation and affordability support.
Clinical therapy management and adherence	Pharmacist counseling, disease-specific protocols, refill outreach, injection training, persistence programs, and clinical escalation.	Major engagement model. Onco360’s public positioning centers on high-touch clinical support for complex cancer care.
Cold chain, REMS, and complex handling	Temperature control, REMS certification, hazardous/controlled-substance handling, biologics, CGT, and other special distribution requirements.	RFP validation point. Treat handling and REMS scope as product-specific diligence rather than assuming every requirement is included.
Manufacturer data and outcomes reporting	Status feeds, dispense data, adherence/outcomes reporting, inventory visibility, and reporting cadence suitable for launch governance.	Documented capability. Onco360 markets manufacturer-facing data and digital support, but buyers should define exact feeds and cadence in the SOW.
Site-of-care, infusion, or health-system coordination	Home infusion, ambulatory infusion, provider-office coordination, health-system capture, and buy-and-bill support where relevant.	Relevant adjacency. Strongest when the therapy crosses oncology practices, hospitals, specialty pharmacy, and payer access workflows.

Buyer Fit

• Right buying motion: Oncology manufacturers needing a focused specialty-pharmacy partner for limited-distribution, narrow-network, or national pharmacy launches.
• Therapy fit: Oral oncology, hematology / oncology, rare cancer, and complex cancer therapies where access support and clinical counseling are part of the launch design.
• Commercial fit: Products where first fill, affordability routing, refill persistence, and manufacturer visibility matter as much as dispensing scale.
• Less ideal fit: Broad multi-therapeutic-area portfolios where the manufacturer wants one generalist specialty pharmacy across many unrelated disease states.
• Diligence lens: Compare Onco360 against PBM-owned specialty pharmacies, wholesaler-owned oncology pharmacies, and rare-disease specialists on payer access, prescriber reach, data rights, patient-services scope, and conflict-of-interest concerns.

Differentiators

• Oncology-only operating model: Onco360’s public identity is built around cancer care rather than oncology as one therapeutic area inside a generalist pharmacy.
• Launch referenceability: Recent public announcements show Onco360 being selected for several oncology therapies, including LIFYORLI, UNLOXCYT, Rigel’s oncology / hematology portfolio, LYNOZYFIC, and PHYRAGO.
• Manufacturer-facing support: The profile is strongest when the manufacturer needs dispensing plus benefit verification, PA support, financial-assistance routing, counseling, adherence outreach, status reporting, and clear handoffs with a separate hub when one is in the program design.
• Independent-positioned channel option: Onco360 can be useful when a manufacturer wants an oncology-focused partner outside the vertically integrated PBM-owned specialty pharmacy stack.
• Clinical and digital support: myOnco360 and manufacturer reporting tools can support patient communication and launch governance, subject to RFP-level data-feed validation.

RFP Questions

• Which oncology therapies and limited-distribution launches are the best analogs for this product?
• What exact benefit-verification, PA, appeal, copay, foundation, and PAP workflows are included before first fill?
• What is the expected referral-to-first-fill timeline, and how is abandonment defined and reported?
• Which dispense, inventory, adherence, refill, adverse-event, and patient-status data fields are available to the manufacturer?
• How does Onco360 coordinate with oncology practices, hospitals, payers, hubs, and any separate field-reimbursement or patient-support vendor?
• Which REMS, cold-chain, hazardous-drug, injectable, or infusion-related requirements can be handled internally versus through partners?

Recent Activity

• March 2026: Onco360 was selected as the national pharmacy partner for LIFYORLI (relacorilant), a Corcept Therapeutics ovarian-cancer therapy.
• January 2026: Onco360 was selected as the national pharmacy partner for UNLOXCYT (cosibelimab-ipdl).
• January 2026: Onco360 partnered with Rigel Pharmaceuticals to add TAVALISSE, GAVRETO, and REZLIDHIA to its limited-distribution portfolio.
• October 2025: Onco360 was selected as a specialty pharmacy partner for PHYRAGO (dasatinib).
• September-October 2025: Onco360 announced national or specialty-pharmacy roles for WAYRILZ (rilzabrutinib) and INLURIYO (imlunestrant).
• August 2025: Onco360 was selected as a specialty pharmacy partner for LYNOZYFIC (linvoseltamab-gcpt).
• June-August 2025: Onco360 public launch announcements included ROMVIMZA (vimseltinib), Augtyro (repotrectinib), and HERNEXEOS (zongertinib).
• June 2025: BrightSpring announced Onco360 selections as a national pharmacy partner for several new cancer and rare-disease drugs.